CRDF
Cardiff Oncology IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$110.76M
P/E Ratio
—
EPS
$-0.69
Beta
1.42
52W High
$4.56
52W Low
$1.48
50-Day MA
$1.74
200-Day MA
$2.25
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | 593,000 |
| Gross Profit (TTM) | $-1.78M |
| EBITDA | $-48.60M |
| Operating Margin | -3221.00% |
| Return on Equity | -71.50% |
| Return on Assets | -38.50% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.66 |
| Price-to-Book | 2.53 |
| Price-to-Sales (TTM) | 186.78 |
| EV/Revenue | 96.78 |
| EV/EBITDA | -3.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 60.90% |
| Shares Outstanding | $68.37M |
| Float | $66.71M |
| % Insiders | 5.91% |
| % Institutions | 36.62% |
Historical Volatility
HV 10-Day
75.48%
HV 20-Day
63.95%
HV 30-Day
59.62%
HV 60-Day
65.14%
HV Rank
32.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($7.75 target)
1
Strong Buy6
Buy1
HoldData last updated: 4/30/2026